The U.S. Food and Drug Administration (FDA) has published a new draft guidance on communications relating to unapproved product uses. The new guide is centered on “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products” (SIUU Guidance). This publication expands the parameters on the allowable dissemination of scientific information on unapproved product uses, also known as “off-label” information, by firms to health care providers (HCPs).
The implementation of this guidance is anticipated to significantly affect how companies can communicate with HCPs about off-label uses of their approved medical products. Previously, regulatory limitations have bound companies from proactively providing information about unapproved uses of their products outside of their FDA-approved label, even when based on sound science. The new draft will likely shift protocols in the health care and pharmaceutical industries.
In formulating the guidance, the FDA aims to strike a balance between ensuring that patients are protected from misleading and unproven claims and allowing for the free exchange of scientific research that could potentially improve patient care and health outcomes. This latest action by the FDA is yet another step in ensuring that HCPs can access necessary information about potential off-label uses of medical products without conflict with existing restrictions.
Further details of this new FDA directive and how it impacts various sectors within the health care and pharmaceutical industries can be perused on jdsupra.com.